Akili Interactive, a digital medicine company developing cognitive treatments through game-changing technologies, went public via merger with Social Capital Suvretta Holdings I, a special purpose acquisition company, in a $1bn deal. The deal included a fully committed PIPE of $162m by Social Capital, Suvretta Capital Management’s Averill strategy, Apeiron Investment Group, Temasek, PureTech Health, Polaris Partners, Evidity Health Capital, JAZZ Venture Partners and Omidyar Technology Ventures. "This transaction represents the next step in our journey to become the world’s leading digital medicine company directly targeting neurological function. Over the past 10 years, we have created a platform representing a new era of cognitive medicine, driven by our fundamental focus on patients, advanced science and proprietary technology, and the mission-driven hard work of our entire team. We believe medicine now can be both effective and engaging. Social Capital Suvretta shares our vision for the future, and we look forward to applying our combined experience as we drive the commercialization of our platform and advance our deep pipeline of prescription digital therapeutics to help people living with cognitive impairments across the globe," Eddie Martucci, Akili CEO.